CDK9-IN-34

CDK9-IN-34 (Compound 1b) is an inhibitor for CDK9 with an IC50 of 0.25 μM. CDK9-IN-34 exhibits cytotoxicity to cancer cell HCT116, MCF7 and K652 with IC50s of 1.43, 3.01 and 50.27 μM, respectively. CDK9-IN-34 exhibits antiviral activity against coronavirus 229E with an IC50 of 145.92 μM[1].

Product Specifications

CAS Number

[252725-86-3]

UNSPSC

12352005

Target

CDK; SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage

Applications

COVID-19-anti-virus

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/cdk9-in-34.html

Purity

99.82

Solubility

DMSO : 12.5 mg/mL (ultrasonic;warming;heat to 60°C)

Smiles

N12C=CN=CC1=NC(C3=CC=CC=C3)=C2NC4CCCCC4

Molecular Formula

C18H20N4

Molecular Weight

292.38

References & Citations

[1]Alsfouk AA, et al., Synthesis and Biological Evaluation of Imadazo[1,2-a]pyrazines as Anticancer and Antiviral Agents through Inhibition of CDK9 and Human Coronavirus. Pharmaceuticals (Basel) . 2022 Jul 13;15 (7) :859.